T cells in multiple sclerosis and experimental autoimmune encephalomyelitis

Clinical and Experimental Immunology

Volumn 162, Issue 1, 2010, Pages 1-11

  Fletcher, J M ^a   Lalor, S J ^a   Sweeney, C M ^a   Tubridy, N ^b   Mills, K H G ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

experimental autoimmune encephalomyelitis; multiple sclerosis; Treg cell; Th1 cell; Th17 cell

Indexed keywords

INTERLEUKIN 17;

ALLERGIC ENCEPHALOMYELITIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL FUNCTION; CELL INTERACTION; CELL MIGRATION; CHRONIC INFLAMMATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HUMAN; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SUPPRESSOR CELL; T LYMPHOCYTE; TH1 CELL; TH17 CELL;

ANIMALS; CELL DIFFERENTIATION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; INTERLEUKIN-17; MODELS, IMMUNOLOGICAL; MULTIPLE SCLEROSIS; T-LYMPHOCYTES; T-LYMPHOCYTES, HELPER-INDUCER; TH1 CELLS;

EID: 77956536780     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2010.04143.x     Document Type: Review

References (117)

1. Frohman EM, Racke MK, Raine CS. Multiple sclerosis-the plaque and its pathogenesis. N Engl J Med 2006 354 : 942 955.
2. Compston A, Coles A. Multiple sclerosis. Lancet 2008 372 : 1502 1517.
3. McDonald WI, Sears TA. The effects of experimental demyelination on conduction in the central nervous system. Brain 1970 93 : 583 598.
4. Polman CH, O'Connor PW, Havrdova E et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006 354 : 899 910.
5. Stromnes IM, Goverman JM. Active induction of experimental allergic encephalomyelitis. Nat Protoc 2006 1 : 1810 1819.
6. Furtado GC, Marcondes MC, Latkowski JA, Tsai J, Wensky A, Lafaille JJ. Swift entry of myelin-specific T lymphocytes into the central nervous system in spontaneous autoimmune encephalomyelitis. J Immunol 2008 181 : 4648 4655.
7. O'Connor RA, Prendergast CT, Sabatos CA et al. Cutting edge: Th1 cells facilitate the entry of Th17 cells to the central nervous system during experimental autoimmune encephalomyelitis. J Immunol 2008 181 : 3750 3754.
8. Steinman L. Assessment of animal models for MS and demyelinating disease in the design of rational therapy. Neuron 1999 24 : 511 514.
9. Stromnes IM, Goverman JM. Passive induction of experimental allergic encephalomyelitis. Nat Protoc 2006 1 : 1952 1960.
10. Teitelbaum D, Meshorer A, Hirshfeld T, Arnon R, Sela M. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol 1971 1 : 242 248.
11. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992 356 : 63 6.
12. Panitch HS, Hirsch RL, Haley AS, Johnson KP. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1987 1 : 893 895.
13. Ferber IA, Brocke S, Taylor-Edwards C et al. Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J Immunol 1996 156 : 5 7.
14. Bettelli E, Sullivan B, Szabo SJ, Sobel RA, Glimcher LH, Kuchroo VK. Loss of T-bet, but not STAT1, prevents the development of experimental autoimmune encephalomyelitis. J Exp Med 2004 200 : 79 87.
15. Cua DJ, Sherlock J, Chen Y et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003 421 : 744 748.
16. Langrish CL, Chen Y, Blumenschein WM et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005 201 : 233 240.
17. Harrington LE, Hatton RD, Mangan PR et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005 6 : 1123 1132.
18. Mangan PR, Harrington LE, O'Quinn DB et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 2006 441 : 231 234.
19. Das J, Ren G, Zhang L et al. Transforming growth factor {beta} is dispensable for the molecular orchestration of Th17 cell differentiation. J Exp Med 2009 206 : 2407 2416.
20. Sutton C, Brereton C, Keogh B, Mills KH, Lavelle EC. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J Exp Med 2006 203 : 1685 1691.
21. Yang L, Anderson DE, Baecher-Allan C et al. IL-21 and TGF-beta are required for differentiation of human T(H)17 cells. Nature 2008 454 : 350 352.
22. Manel N, Unutmaz D, Littman DR. The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat Immunol 2008 9 : 641 649.
23. Wilson NJ, Boniface K, Chan JR et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007 8 : 950 957.
24. Santarlasci V, Maggi L, Capone M et al. TGF-beta indirectly favors the development of human Th17 cells by inhibiting Th1 cells. Eur J Immunol 2009 39 : 207 215.
25. Hofstetter HH, Ibrahim SM, Koczan D et al. Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis. Cell Immunol 2005 237 : 123 130.
26. Komiyama Y, Nakae S, Matsuki T et al. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol 2006 177 : 566 573.
27. Haak S, Croxford AL, Kreymborg K et al. IL-17A and IL-17F do not contribute vitally to autoimmune neuro-inflammation in mice. J Clin Invest 2009 119 : 61 9.
28. Coquet JM, Chakravarti S, Smyth MJ, Godfrey DI. Cutting edge: IL-21 is not essential for Th17 differentiation or experimental autoimmune encephalomyelitis. J Immunol 2008 180 : 7097 7101.
29. Kreymborg K, Etzensperger R, Dumoutier L et al. IL-22 is expressed by Th17 cells in an IL-23-dependent fashion, but not required for the development of autoimmune encephalomyelitis. J Immunol 2007 179 : 8098 8104.
30. Nowak EC, Weaver CT, Turner H et al. IL-9 as a mediator of Th17-driven inflammatory disease. J Exp Med 2009 206 : 1653 1660.
31. Lees JR, Iwakura Y, Russell JH. Host T cells are the main producers of IL-17 within the central nervous system during initiation of experimental autoimmune encephalomyelitis induced by adoptive transfer of Th1 cell lines. J Immunol 2008 180 : 8066 8072.
32. Kroenke MA, Carlson TJ, Andjelkovic AV, Segal BM. IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition. J Exp Med 2008 205 : 1535 1541.
33. Stromnes IM, Cerretti LM, Liggitt D, Harris RA, Goverman JM. Differential regulation of central nervous system autoimmunity by T(H)1 and T(H)17 cells. Nat Med 2008 14 : 337 342.
34. Abromson-Leeman S, Bronson RT, Dorf ME. Encephalitogenic T cells that stably express both T-bet and RORgammat consistently produce IFNgamma but have a spectrum of IL-17 profiles. J Neuroimmunol 2009 215 : 10 24.
35. Shi G, Cox CA, Vistica BP, Tan C, Wawrousek EF, Gery I. Phenotype switching by inflammation-inducing polarized Th17 cells, but not by Th1 cells. J Immunol 2008 181 : 7205 7213.
36. Yang Y, Weiner J, Liu Y et al. T-bet is essential for encephalitogenicity of both Th1 and Th17 cells. J Exp Med 2009 206 : 1549 1564.
37. Gocke AR, Cravens PD, Ben LH et al. T-bet regulates the fate of Th1 and Th17 lymphocytes in autoimmunity. J Immunol 2007 178 : 1341 1348.
38. Thakker P, Leach MW, Kuang W, Benoit SE, Leonard JP, Marusic S. IL-23 is critical in the induction but not in the effector phase of experimental autoimmune encephalomyelitis. J Immunol 2007 178 : 2589 2598.
39. Gyulveszi G, Haak S, Becher B. IL-23-driven encephalo-tropism and Th17 polarization during CNS-inflammation in vivo. Eur J Immunol 2009 39 : 1864 1869.
40. Reboldi A, Coisne C, Baumjohann D et al. C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol 2009 10 : 514 523.
41. Sallusto F, Lanzavecchia A. Human Th17 cells in infection and autoimmunity. Microbes Infect 2009 11 : 620 624.
42. Lock C, Hermans G, Pedotti R et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002 8 : 500 508.
43. Montes M, Zhang X, Berthelot L et al. Oligoclonal myelin-reactive T-cell infiltrates derived from multiple sclerosis lesions are enriched in Th17 cells. Clin Immunol 2009 130 : 133 144.
44. Tzartos JS, Friese MA, Craner MJ et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 2008 172 : 146 155.
45. Matusevicius D, Kivisakk P, He B et al. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 1999 5 : 101 104.
46. Durelli L, Conti L, Clerico M et al. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta. Ann Neurol 2009 65 : 499 509.
47. Frisullo G, Nociti V, Iorio R et al. IL17 and IFNgamma production by peripheral blood mononuclear cells from clinically isolated syndrome to secondary progressive multiple sclerosis. Cytokine 2008 44 : 22 5.
48. Kebir H, Kreymborg K, Ifergan I et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med 2007 13 : 1173 1175.
49. Kebir H, Ifergan I, Alvarez JI et al. Preferential recruitment of interferon-gamma-expressing T(H)17 cells in multiple sclerosis. Ann Neurol 2009 66 : 390 402.
50. Sawcer S, Ban M, Maranian M et al. A high-density screen for linkage in multiple sclerosis. Am J Hum Genet 2005 77 : 454 467.
51. Friese MA, Fugger L. Pathogenic CD8(+) T cells in multiple sclerosis. Ann Neurol 2009 66 : 132 141.
52. Weiss HA, Millward JM, Owens T. CD8+ T cells in inflammatory demyelinating disease. J Neuroimmunol 2007 191 : 79 85.
53. Chen ML, Yan BS, Kozoriz D, Weiner HL. Novel CD8(+) regulatory T cells suppress experimental autoimmune encephalomyelitis by TGF-beta- and IFN-gamma-dependent mechanisms. Eur J Immunol 2009 39 : 3423 3435.
54. Wucherpfennig KW, Newcombe J, Li H, Keddy C, Cuzner ML, Hafler DA. Gamma delta T-cell receptor repertoire in acute multiple sclerosis lesions. Proc Natl Acad Sci USA 1992 89 : 4588 4592.
55. Shimonkevitz R, Colburn C, Burnham JA, Murray RS, Kotzin BL. Clonal expansions of activated gamma/delta T cells in recent-onset multiple sclerosis. Proc Natl Acad Sci USA 1993 90 : 923 927.
56. Kobayashi Y, Kawai K, Ito K, Honda H, Sobue G, Yoshikai Y. Aggravation of murine experimental allergic encephalomyelitis by administration of T-cell receptor gammadelta-specific antibody. J Neuroimmunol 1997 73 : 169 174.
57. Ponomarev ED, Dittel BN. Gamma delta T cells regulate the extent and duration of inflammation in the central nervous system by a Fas ligand-dependent mechanism. J Immunol 2005 174 : 4678 4687.
58. Ponomarev ED, Novikova M, Yassai M, Szczepanik M, Gorski J, Dittel BN. Gamma delta T cell regulation of IFN-gamma production by central nervous system-infiltrating encephalitogenic T cells: correlation with recovery from experimental autoimmune encephalomyelitis. J Immunol 2004 173 : 1587 1595.
59. Rajan AJ, Gao YL, Raine CS, Brosnan CF. A pathogenic role for gamma delta T cells in relapsing-remitting experimental allergic encephalomyelitis in the SJL mouse. J Immunol 1996 157 : 941 949.
60. Rajan AJ, Klein JD, Brosnan CF. The effect of gammadelta T cell depletion on cytokine gene expression in experimental allergic encephalomyelitis. J Immunol 1998 160 : 5955 5962.
61. Spahn TW, Issazadah S, Salvin AJ, Weiner HL. Decreased severity of myelin oligodendrocyte glycoprotein peptide 33-35-induced experimental autoimmune encephalomyelitis in mice with a disrupted TCR delta chain gene. Eur J Immunol 1999 29 : 4060 4071.
62. Odyniec A, Szczepanik M, Mycko MP, Stasiolek M, Raine CS, Selmaj KW. Gammadelta T cells enhance the expression of experimental autoimmune encephalomyelitis by promoting antigen presentation and IL-12 production. J Immunol 2004 173 : 682 694.
63. Cardona AE, Teale JM. Gamma/delta T cell-deficient mice exhibit reduced disease severity and decreased inflammatory response in the brain in murine neurocysticercosis. J Immunol 2002 169 : 3163 3171.
64. Koenecke C, Chennupati V, Schmitz S, Malissen B, Forster R, Prinz I. In vivo application of mAb directed against the gammadelta TCR does not deplete but generates 'invisible' gammadelta T cells. Eur J Immunol 2009 39 : 372 379.
65. Lockhart E, Green AM, Flynn JL. IL-17 production is dominated by gammadelta T cells rather than CD4 T cells during Mycobacterium tuberculosis infection. J Immunol 2006 177 : 4662 4669.
66. Shibata K, Yamada H, Hara H, Kishihara K, Yoshikai Y. Resident Vdelta1+ gammadelta T cells control early infiltration of neutrophils after Escherichia coli infection via IL-17 production. J Immunol 2007 178 : 4466 4472.
67. Sutton CE, Lalor SJ, Sweeney CM, Brereton CF, Lavelle EC, Mills KH. Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. Immunity 2009 31 : 331 341.
68. Hori S, Sakaguchi S. Foxp3: a critical regulator of the development and function of regulatory T cells. Microbes Infect 2004 6 : 745 751. (Pubitemid 38781186)
69. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003 4 : 330 336.
70. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995 155 : 1151 1164.
71. Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 2006 212 : 28 50.
72. Liston A, Rudensky AY. Thymic development and peripheral homeostasis of regulatory T cells. Curr Opin Immunol 2007 19 : 176 185.
73. Curotto de Lafaille MA, Lafaille JJ. Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? Immunity 2009 30 : 626 635.
74. Liu W, Putnam AL, Xu-Yu Z et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006 203 : 1701 1711.
75. Martinez-Forero I, Garcia-Munoz R, Martinez-Pasamar S et al. IL-10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis. Eur J Immunol 2008 38 : 576 586.
76. Astier AL, Meiffren G, Freeman S, Hafler DA. Alterations in CD46-mediated Tr1 regulatory T cells in patients with multiple sclerosis. J Clin Invest 2006 116 : 3252 3257.
77. Venken K, Hellings N, Thewissen M et al. Compromised CD4+ CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level. Immunology 2008 123 : 79 89.
78. + regulatory T cells in the cerebrospinal fluid but not in the blood of multiple sclerosis patients. Clin Exp Immunol 2007 147 : 412 418.
79. Haas J, Hug A, Viehover A et al. Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. Eur J Immunol 2005 35 : 3343 3352.
80. Venken K, Hellings N, Hensen K et al. Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression. J Neurosci Res 2006 83 : 1432 1446.
81. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 2004 199 : 971 979.
82. Tsaknaridis L, Spencer L, Culbertson N et al. Functional assay for human CD4+CD25+ Treg cells reveals an age-dependent loss of suppressive activity. J Neurosci Res 2003 74 : 296 308.
83. Huan J, Culbertson N, Spencer L et al. Decreased FOXP3 levels in multiple sclerosis patients. J Neurosci Res 2005 81 : 45 52.
84. Frisullo G, Nociti V, Iorio R et al. Regulatory T cells fail to suppress CD4(+)T-bet(+) T cells in relapsing multiple sclerosis patients. Immunology 2008 127 : 418 428.
85. Venken K, Thewissen M, Hellings N et al. A CFSE based assay for measuring CD4+CD25+ regulatory T cell mediated suppression of auto-antigen specific and polyclonal T cell responses. J Immunol Methods 2007 322 : 1 11.
86. de Andres C, Aristimuno C, de Las Heras V et al. Interferon beta-1a therapy enhances CD4+ regulatory T-cell function: an ex vivo and in vitro longitudinal study in relapsing-remitting multiple sclerosis. J Neuroimmunol 2007 182 : 204 211.
87. Kumar M, Putzki N, Limmroth V et al. CD4+CD25+FoxP3+ T lymphocytes fail to suppress myelin basic protein-induced proliferation in patients with multiple sclerosis. J Neuroimmunol 2006 180 : 178 184.
88. Korporal M, Haas J, Balint B et al. Interferon beta-induced restoration of regulatory T-cell function in multiple sclerosis is prompted by an increase in newly generated naive regulatory T cells. Arch Neurol 2008 65 : 1434 1439.
89. Hong J, Li N, Zhang X, Zheng B, Zhang JZ. Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc Natl Acad Sci USA 2005 102 : 6449 6454.
90. Xu L, Xu Z, Xu M. Glucocorticoid treatment restores the impaired suppressive function of regulatory T cells in patients with relapsing-remitting multiple sclerosis. Clin Exp Immunol 2009 158 : 26 30.
91. Michel L, Berthelot L, Pettre S et al. Patients with relapsing-remitting multiple sclerosis have normal Treg function when cells expressing IL-7 receptor alpha-chain are excluded from the analysis. J Clin Invest 2008 118 : 3411 3419.
92. Fletcher JM, Lonergan R, Costelloe L et al. CD39+Foxp3+ regulatory T cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis. J Immunol 2009 183 : 7602 7610.
93. Lafaille JJ, Nagashima K, Katsuki M, Tonegawa S. High incidence of spontaneous autoimmune encephalomyelitis in immunodeficient anti-myelin basic protein T cell receptor transgenic mice. Cell 1994 78 : 399 408.
94. Olivares-Villagomez D, Wang Y, Lafaille JJ. Regulatory CD4(+) T cells expressing endogenous T cell receptor chains protect myelin basic protein-specific transgenic mice from spontaneous autoimmune encephalomyelitis. J Exp Med 1998 188 : 1883 1894.
95. Kohm AP, Carpentier PA, Anger HA, Miller SD. Cutting edge: CD4+CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. J Immunol 2002 169 : 4712 4716.
96. Zhang X, Koldzic DN, Izikson L et al. IL-10 is involved in the suppression of experimental autoimmune encephalomyelitis by CD25+CD4+ regulatory T cells. Int Immunol 2004 16 : 249 256.
97. Walsh KP, Brady MT, Finlay CM, Boon L, Mills KH. Infection with a helminth parasite attenuates autoimmunity through TGF-beta-mediated suppression of Th17 and Th1 responses. J Immunol 2009 183 : 1577 1586.
98. Reddy J, Illes Z, Zhang X et al. Myelin proteolipid protein-specific CD4+CD25+ regulatory cells mediate genetic resistance to experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 2004 101 : 15434 15439.
99. Stephens LA, Gray D, Anderton SM. CD4+CD25+ regulatory T cells limit the risk of autoimmune disease arising from T cell receptor crossreactivity. Proc Natl Acad Sci USA 2005 102 : 17418 17423.
100. Korn T, Reddy J, Gao W et al. Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat Med 2007 13 : 423 431.
101. Liu Y, Teige I, Birnir B, Issazadeh-Navikas S. Neuron-mediated generation of regulatory T cells from encephalitogenic T cells suppresses EAE. Nat Med 2006 12 : 518 525.
102. McGeachy MJ, Stephens LA, Anderton SM. Natural recovery and protection from autoimmune encephalomyelitis: contribution of CD4+CD25+ regulatory cells within the central nervous system. J Immunol 2005 175 : 3025 3032.
103. Zhang X, Reddy J, Ochi H, Frenkel D, Kuchroo VK, Weiner HL. Recovery from experimental allergic encephalomyelitis is TGF-beta dependent and associated with increases in CD4+LAP+ and CD4+CD25+ T cells. Int Immunol 2006 18 : 495 503.
104. O'Connor RA, Malpass KH, Anderton SM. The inflamed central nervous system drives the activation and rapid proliferation of Foxp3+ regulatory T cells. J Immunol 2007 179 : 958 966.
105. Cox AL, Thompson SA, Jones JL et al. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur J Immunol 2005 35 : 3332 3342.
106. Coles AJ, Compston DA, Selmaj KW et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008 359 : 1786 1801.
107. Stephens LA, Malpass KH, Anderton SM. Curing CNS autoimmune disease with myelin-reactive Foxp3+ Treg. Eur J Immunol 2009 39 : 1108 1117.
108. Lima XT, Abuabara K, Kimball AB, Lima HC. Briakinumab. Exp Opin Biol Ther 2009 9 : 1107 1113.
109. Melnikova I. Psoriasis market. Nat Rev Drug Discov 2009 8 : 767 768.
110. van den Berg WB, Miossec P. IL-17 as a future therapeutic target for rheumatoid arthritis. Nat Rev Rheumatol 2009 5 : 549 553.
111. Segal BM, Constantinescu CS, Raychaudhuri A, Kim L, Fidelus-Gort R, Kasper LH. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol 2008 7 : 796 804.
112. Longbrake EE, Racke MK. Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis? Expert Rev Neurother 2009 9 : 319 321.
113. Mills KH. Induction, function and regulation of IL-17-producing T cells. Eur J Immunol 2008 38 : 2636 2649.
114. Chen Y, Langrish CL, McKenzie B et al. Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J Clin Invest 2006 116 : 1317 1326.
115. Eugster HP, Frei K, Kopf M, Lassmann H, Fontana A. IL-6-deficient mice resist myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. Eur J Immunol 1998 28 : 2178 2187.
116. Korn T, Mitsdoerffer M, Croxford AL et al. IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells. Proc Natl Acad Sci USA 2008 105 : 18460 18465.
117. Kleinschek MA, Owyang AM, Joyce-Shaikh B et al. IL-25 regulates Th17 function in autoimmune inflammation. J Exp Med 2007 204 : 161 170.